Targeting bacteria in the gut could increase effectiveness of levodopa
New research from Harvard University suggests changes to the gut could improve how a common Parkinson’s medication works.
New molecules targeting alpha-synuclein have potential for slowing Parkinson’s
Researchers in Japan have developed molecules that could be key to slowing the progression of Parkinson’s.
Existing drugs may help the brain protect itself against Parkinson's
Researchers at King's College London have investigated the properties of over 1,000 approved drugs to identify 2 with potential for Parkinson's.
New mouse model highlights promising potential drug for slowing Parkinson’s
The results indicate that, when given early, the molecule Anle138b may restore dopamine levels and help slow or stop Parkinson’s in its tracks.
Repurposed drug enters clinical trial for Lewy body dementia
Researchers in the US have launched a clinical trial to test a drug with the potential to slow the progression of Lewy body dementia.
Test to detect early Parkinson's given FDA Breakthrough Device Designation
The biotech company Amprion have developed a test to detect the early signs of Parkinson's, before the onset of symptoms, which they hope will be ready to market in the next 18 months.
New study suggests that having bipolar disorder increases the risk of Parkinson's
People with bipolar disorder are almost 7 times more likely to develop Parkinson's than those without the condition, according to new research published in the journal Neurology.
New insights into the link between the appendix and Parkinson's
The media reports on a large-scale study that suggests the removal of the appendix may increase the risk of Parkinson's.
Phase II trial is underway investigating a gene therapy for Parkinson's
Axovant Gene Therapies Ltd., a company developing innovative gene therapies, has announced they are entering the next stage of a phase II gene therapy trial for Parkinson's.
Blood pressure drug fails in phase 3 Parkinson's trial
The STEADY-PD clinical trial has failed to show that isradipine is an effective treatment to slow or stop progression in early Parkinson's.